Peripheral Stem Cell Transplantation Plus Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma

• Status: Completed
• Trial end date: 2002-12-01

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. Monoclonal antibodies can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells.

PURPOSE: Phase II trial to study the effectiveness of peripheral stem cell transplantation plus combination chemotherapy and rituximab in treating patients with non-Hodgkin's lymphoma.

• Phase: Phase 2

Details

• Lead Sponsor: University of Maryland; University of Maryland, Baltimore
• Collaborator: University of Maryland Greenebaum Cancer Center
• Treatments: Carmustine; Cyclophosphamide; Dexamethasone; Etoposide; Gemcitabine; Melphalan; Paclitaxel; Rituximab; Sargramostim